OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Paraparesis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,764 reports · 58 co-occurring drugs

As of the last recalculation, Paraparesis appears in 1,764 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is SIPONIMOD (PRR 22.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Siponimod1722.722.7
Bleomycin Sulfate1921.922.0
Fingolimod Hcl14421.321.3
Gentamicin2220.120.1
Gentamicin Sulfate2418.218.2
Alemtuzumab2716.716.7
Bupivacaine1316.516.6
Goserelin1715.115.1
Ado-Trastuzumab Emtansine1014.114.1
Abacavir Sulfate1113.413.4
Cytarabine5912.012.0
Fludarabine Phosphate3611.011.0
Baclofen7310.410.4
Lamivudine Oral219.99.9
Ocrelizumab509.89.8
Vismodegib79.39.3
Dalfampridine559.39.3
Interferon Beta-1B159.39.3
Brentuximab Vedotin89.29.3
Lapatinib129.29.2
Itraconazole99.19.1
Busulfan129.19.1
Temozolomide169.09.0
Ofatumumab259.09.0
Haloperidol188.88.8
Etoposide538.78.7
Iron Sucrose78.78.7
Haloperidol Lactate188.78.7
Fentanyl Citrate138.68.6
Efavirenz88.58.5
Tizanidine178.58.5
Clarithromycin248.38.4
Teriflunomide318.28.2
Lamivudine218.18.1
Pertuzumab187.97.9
Bendamustine Hcl107.67.7
Pyrazinamide67.67.6
Mercaptopurine117.57.5
Cyclophosphamide Injection, Solution1067.57.5
Cyclophosphamide1067.57.5
Cyclophosphamide For Injection1067.57.5
Abiraterone87.07.0
Vemurafenib76.96.9
Doxorubicin486.56.5
Docetaxel Anhydrous346.16.1
Docetaxel346.06.1
Glatiramer Acetate306.06.0
Paliperidone115.65.6
Capecitabine395.15.1
Interferon Beta-1A805.15.1
Natalizumab704.74.7
Dimethyl Fumarate464.54.5
Nivolumab364.54.5
Eltrombopag Olamine73.63.6
Ipilimumab133.63.6
Ledipasvir And Sofosbuvir53.13.1
Abiraterone Acetate102.92.9
Lutetium Lu 177 Vipivotide Tetraxetan32.72.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.